期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

自体CIK细胞维持治疗晚期非小细胞肺癌临床观察 被引量：2

The use of autologous CIK cells in the maintenance treatment of advanced NSCLC
下载PDF
导出
摘要 目的探讨自体CIK细胞对晚期非小细胞肺癌(Non-small cell lung cancer,NSCLC)维持治疗的临床效果。方法对16例晚期NSCLC患者在手术、放疗、化疗获益基础上,采用自体CIK进行维持治疗。结果患者使用自体CIK细胞治疗后,短期内生存质量有所提高,未发现严重毒副作用。结论自体CIK细胞治疗晚期非小细胞肺癌有控制肿瘤、增强患者免疫功能、改善生存质量(Quality of Life,QOL)以及延长生存期的趋势。 Objective To observe the clinical efficacy of autologous cytokine-induced killer（CIK） cells in the maintenance treatment of advanced non-small-cell lung cancer（NSCLC）.Methods 16 advanced NSCLC patients after surgery,radiotherapy or chemotherapy were treated with autologous CIK cells.Results Patients treated with autologous CIK cells had an improvement of their quality of life and had no serious side-effect.Conclusion The use of autologous CIK cells to treat advanced NSCLC has advantages of enhancing immune function,improving the quality of life and prolonging overall survival.
作者 邵青 杨卫兵 余丽梅 章涛 李宁 柏玉举 石磊 岳国军 张廷友 郑召鹏 黄丽斌
机构地区 遵义医学院附属肿瘤医院
出处 《西部医学》 2011年第9期1641-1643,共3页 Medical Journal of West China
基金 贵州省优秀科技教育人才省长专项资金项目(黔省专合字:2009-46号)
关键词 自体CIK细胞 非小细胞肺癌 维持治疗 Autologous cytokine-induced killer（CIK） cells Non-small-cell lung cancer Maintenance treatment
分类号 R734.2 [医药卫生—肿瘤]
  • 相关文献

参考文献16

  • 1Pao W, Girard N. New driver mutations in non-small-cell lung cancer[J]. The lancet oncology,2011,12(2) : 175-180.
  • 2刘启亮.自体CIK细胞治疗晚期非小细胞肺癌30例[J].西南军医,2009,11(6):1091-1092. 被引量：7
  • 3Hontscha C, Borck Y, Zhou H, et al. Clinical trials on CIK ceils: first report of the international registry on CIK ceils (IRCC) [J]. Journal of cancer research and clinical oncology,2010,137(2):305-310.
  • 4Schmidt-Wolf I, Negrin RS, Kiem HP, et al. Use of a SCID mouse/human lymphoma model to evaluate eytokine-indueed killer ceils with potent antitumor cell activity[J]. The Journal of experimental medicine, 1991, 174(1) : 139-149.
  • 5Chang A. Chemotherapy, ehemoresistance and the changing treatment landscape for NSCLCFJ]. Lung cancer, 2011, 71(1): 3-10.
  • 6Levina V, Marrangoni A, Wang T, et al. Elimination of Human Lung Cancer Stem Cells through Targeting of the Stem Cell Factor-c-klt Autoerine Signaling Loop[J]. Cancer research, 2010, 70(1) 1338-346.
  • 7Hsu HS, Huang PI, Chang YL, etal. Cucurbitacin i inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells[J]. Cancer, 2011, (000) ;000-000.
  • 8Baas P, Belderbos JSA, van den Heuvel M. Chemoradiation therapy in nonsmall cell lung cancer[J]. Current Opinion in Oncology ,2011,23(2) :140-149.
  • 9Blattman JN, Greenberg PD. Cancer immunotherapy, a treatment for the masses[J]. Science, 2004, 305(5681):200-205.
  • 10Introna M, Borleri G, Conti E, et al. Repeated infusions of donor-derived eytokine-indueed killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study[J]. Haematologica, 2007, 92(7):952-959.

二级参考文献14

  • 1郭勇.190例癌症患者临床辨证分析的思考[J].中国中医基础医学杂志,2000,6(10):44-47. 被引量：44
  • 2Scagliotti GV, Parikh P, yon Pawel J, et al. Phase Ⅲ study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non- small-cell lung cancer [ J]. J Clin Oneol, 2008, 26:3543 -3551.
  • 3Han JY, Lee DH, Song JE, et al. Randomized phase 2 study of irinotecan plus cisplatin versus gemcitabine plus vinorelbine as first-line chemotherapy with second-line crossover in patients with advanced nonsmall cell lung cancer[J]. Cancer, 2008,113:388 - 395.
  • 4Mencoboni M, Bergaglio M, Serra M, et al. Maintenance therapy with gefitinib after first - line chemotherapy in patients affected by advanced non - small cell lung cancer [ J ]. Anticancer Res, 2007,27:4425 -4429.
  • 5Kelly K, Chansky K, Gaspar LE, et al. Phase Ⅲ trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage Ⅲ non - small - cell lung cancer: SWOG S0023 [ J ]. J Clin Oncol, 2008,26:2450 - 2456.
  • 6Brodowicz T, Krzakowski M, Zwitter M, et al. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best supportive care in advanced non-small cell lung cancer: a phase Ⅲ trial[J]. Lung Cancer,2006, 52:155 - 163.
  • 7Fidias PM, Dakhil SR, Lyss AP, et al. Phase Ⅲ Study of Immediate Compared With Delayed Docetaxel After Front - Line Therapy With Gemcitabine Plus Carboplatin in Advanced Non - Small -Cell Lung Cancer[J]. J Clin Oncol, 2009,27 (4):591 -598.
  • 8Xu JM, Han Y, Li YM, et at. Phase Ⅱ trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non - small - cell lung cancer [J]. BMC Cancer, 2006,16:288.
  • 9Ng R, Loreto M, Lee R, et al. Brief report : retrospective review of efficacy of erlotinib or gefitinib compared to doeetaxel as subsequent line therapy in advanced non-small cell lung cancer (NSCLC) following failure of platinum-based chemotherapy[ J ]. Lung Cancer, 2008,61:262 - 265.
  • 10Giaceone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase Ⅲ trial--INTACT 1 [ J]. J Clin Oncol, 2004,22 : 777 -784.

共引文献17

同被引文献26

  • 1Jemal A, Siegel R, Xu J, et al.Cancer statistics 2010[J]. CA Cancer J Clin, 2010, 60(5) :277-300.
  • 2Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance peme- trexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study [ J ]. Lancet, 2009, 374 (9699) : 1432-1440.
  • 3Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as mainte- nance treatment in advanced non-small-cell lung cancer: a multi- centre, randomised, placebo-controlled phase 3 study [ J ]. Lancet oncol, 2010, 11(6) : 521-529.
  • 4Gunzer M, Janich S, Varga G, et al. Dendritic cells and tumor immunity[J]. Semin immunol, 2001, 13(5): 291-302.
  • 5Zhong C, Liu H, Jiang L, et al. Chemotherapy plus best support- ive care versus best supportive care in patients with non-small cell lung cancer : a meta-analysis of randomized controlled trials [ J/ OL]. PLoS One, 2013 [ 2014-02-20]. http://www. ncbi. nlm. nih. gov/pmc/artieles/pmid/23555583.
  • 6Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer[ J]. N Engl J Med, 2006, 355(24): 2542-2550.
  • 7Pirker R, Pereira JR, Szczesna A, et al. Cetuximah plus chemo- therapy in patients with advanced non-small-cell lung cancer (FLEX) : an open-label randomised phase III trial [ J]. Lancet, 2009, 373(9674) : 1525-1531.
  • 8Shi SB, Ma TH, Li CH, et al. Effect of maintenance therapy with dendritic cells : cytokine-induced killer cells in patients with advanced non-small cell lung cancer [ J]. Tumori, 2012, 98 (3) : 314.
  • 9张蕾,李平.生活质量在肿瘤治疗疗效评价中的应用[J].临床肺科杂志,2008,13(1):68-69. 被引量：6
  • 10Jemal A, Bray F, Center MM, et al. Global cancer statistics[ J].CA Cancer J Clin, 2011,61 (2) :69 -90.

引证文献2

二级引证文献11

西部医学
2011年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部